Streetbeat News

CALC

CalciMedica, Inc.

https://www.calcimedica.com

Industry

Biotechnology

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Open

3.50

Mkt cap

47M

Volume

113K

High

3.57

P/E Ratio

-20.41

52-wk high

8.38

Low

3.41

Div yield

N/A

52-wk low

2.68

CalciMedica, a clinical-stage biopharmaceutical company, has appointed Stephen Bardin as its new Chief Financial Officer, replacing Interim CFO Daniel Geffken. This leadership change comes as the company focuses on developing CRAC channel inhibition therapies.

Portfolio Pulse from

November 07, 2024 | 12:15 pm

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

CalciMedica's stock is trading lower following the announcement of a $10.2 million common stock offering.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:45 pm

The article highlights significant pre-market movements in healthcare stocks on Thursday. Notable gainers include Autonomix Medical, Tenon Medical, and Aerovate Therapeutics, while Matinas BioPharma and Equillium are among the biggest losers. Several companies reported Q3 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:10 pm

Several healthcare stocks experienced significant price movements in Thursday's pre-market session. Notable gainers include Autonomix Medical, Tenon Medical, and Alphatec Holdings, while Matinas BioPharma and Equillium saw substantial declines.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:09 pm

Carvana Co. (NYSE:CVNA) shares surged over 20% in pre-market trading after reporting better-than-expected Q3 financial results, with revenue and earnings per share surpassing analyst estimates. Other notable pre-market movers include Root, Inc. (NASDAQ:ROOT) and Alphatec Holdings, Inc. (NASDAQ:ATEC), both rising significantly due to strong quarterly results.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 10:52 am

CalciMedica, Inc. (NASDAQ:CALC) has announced a $10.2 million stock offering to fund its research on inflammatory diseases. The company is offering 2.72 million shares at $3.75 each, with an option for underwriters to purchase an additional 408,000 shares. The offering is expected to close by November 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 8:18 am

CalciMedica, Inc. (NASDAQ:CALC) has announced a proposed public offering of its common stock, though the size and amount have not been disclosed. The offering is subject to market conditions, and Jones is the sole book-running manager.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:13 pm

Several health care stocks experienced significant price movements during Wednesday's intraday session. Notable gainers included Tharimmune, Ensysce Biosciences, Xilio Therapeutics, Omnicell, CVRx, and CalciMedica. On the losing side, Applied DNA Sciences, AnaptysBio, Sage Therapeutics, Option Care Health, Cormedix, and Hims & Hers Health saw declines. The movements were influenced by recent earnings reports and market reactions.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 4:31 pm

CalciMedica shares rose following the announcement of positive Phase 2B trial results for auxora in treating acute pancreatitis with systemic inflammatory response syndrome.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 2:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.